Demographic, clinical, and imaging characteristics of the studied sample with CLL compared with those without CLL
| Total (n = 139) | Patients with CLL (n = 23) | Patients without CLL (n = 116) | P Value | |
|---|---|---|---|---|
| Age at cranial RT (median) (minimum-maximum) (yr) | 6 (0–15) | 9 (1–17) | .004a | |
| Primary CNS tumor, No. (%) | .044a | |||
| Medulloblastoma | 52 | 14 (26.9) | 38 (73.1) | |
| Ependymoma | 22 | 4 (18.2) | 18 (82.8) | |
| Germinal cell tumor | 19 | 2 (10.5) | 17 (89.5) | |
| Others | 46 | 3 (6.5) | 43 (93.5) | |
| Location, No. (%) | .725b | |||
| Infratentorial | 80 | 14 (17.5) | 66 (82.5) | |
| Supratentorial | 59 | 9 (15.3) | 50 (84.7) | |
| RT technique, No. (%) | .341a | |||
| WBRT | 3 | 0 (0) | 3 (100) | |
| Focal | 64 | 8 (79.2) | 56 (87.5) | |
| WBRT + focal | 72 | 15 (20.8) | 57 (79.2) | |
| RT total dose (median) (minimum-maximum) (Gy) | 54 (20–90) | 54 (50–60) | .294a | |
| Treatment protocol, No. (%) | .027a | |||
| No chemoradiotherapy | 109 | 14 (12.8) | 95 (87.2) | |
| Chemoradiotherapy | 29 | 9 (31.0) | 20 (69.0) | |
| Chemotherapy regimen, No. (%) | .584b | |||
| No Chemotherapy | 41 | 5 (12.2) | 36 (87.8) | |
| Chemotherapy with MTX | 8 | 2 (25.0) | 6 (75.0) | |
| Chemotherapy without MTX | 90 | 16 (17.8) | 74 (82.2) |